Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M versus HEPATASOL 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M versus HEPATASOL 8.
AMINOSYN II 3.5% M vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids for protein synthesis, serving as substrates for anabolic processes in parenteral nutrition.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous infusion of 1.2 to 2.2 g amino acids per kg per day, adjusted to meet metabolic and nutritional requirements. Typical adult dose: initial infusion rate of 50 mL/hour, increasing to 125 mL/hour (4.4 g amino acids per hour) based on tolerance. Not for direct peripheral administration without supplementation of electrolytes and/or dextrose.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
The terminal elimination half-life of amino acids from the infusion mixture is not uniformly defined; however, individual amino acids have half-lives ranging from 10 to 30 minutes. For the mixture, the effective half-life is clinically considered to be approximately 1-2 hours, reflecting rapid metabolic clearance. In renal impairment, the half-life may be prolonged due to reduced urea clearance.
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Aminosyn II 3.5% M is a crystalline amino acid solution. Amino acids are primarily eliminated by metabolic utilization for protein synthesis and energy production. Excess amino acids undergo deamination, with nitrogen excreted as urea in urine via renal route. Fecal and biliary excretion are negligible. Approximately 80-90% of infused nitrogen is recovered as urea in urine in patients with normal renal function.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution